Welcome to CDC stacks | Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003 - 7296 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Previous Button
Previous Button
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection---United States, 2003
Record #: 275 of 792
Next Button
  • Published Date:
    August 8, 2003
  • Status:
    current
  • Source:
    MMWR. Morbidity and mortality weekly report. 2003; 52(31):735-9.
  • Language:
    English
Next Button
Filetype[HTML]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Keywords:
  • Pubmed ID:
    12904741
  • Description:
    A previously published report provided guidelines for managing the pharmacologic interactions that can result when patients receive protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs) for treatment of human immunodeficiency virus (HIV) infection together with rifamycins for the treatment of tuberculosis (TB). Protease inhibitors and NNRTIs are antiretroviral agents that are substrates that may inhibit or induce cytochrome P-450 isoenzymes (CYP450). Rifamycins are antituberculosis agents that induce CYP450 and may decrease substantially blood levels of the antiretroviral drugs. The pharmacologic interactions are called "drug-drug" because, in addition to the effect rifamycins have on protease inhibitors and NNRTIs, the antiretroviral agents may affect the blood levels of rifamycins. This notice presents updated data pertaining to drug-drug interactions between these agents and recommendations for their use from a group of CDC scientists and outside expert consultants.

  • Document Type:
    Journal Article
  • Collection(s):
    Guidelines and Recommendations
  • Place as Subject:
    United States
  • Main Document Checksum:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. MMWR. Morbidity and mortality weekly report, Vol. 52, no. 31, August 8, 2003
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    August 8, 2003
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 52, no. 31
    Description:
    Imported Plague--New York City, 2002 -- National, State, and Urban Area Vaccination Levels Among Children Aged 19-35 Months--United States, 2002 -- Vaccination Services in Postwar Iraq, May 2003 -- Update: Adverse Event Data and Revised American Thor...
    File Type:
    Filetype[PDF - 587.17 KB]
  2. TB facts for health care workers 2006
    Corporate Author:
    National Center for HIV, STD, and TB Prevention (U.S.), Division of Tuberculosis Elimination.
    Published:
    2006
    Description:
    Glossary of abbreviations -- Tuberculosis - yes! It's still a problem -- Populations at risk for tuberculosis -- Mode of transmission -- Identification of persons with latent TB infection and TB disease -- Prevention of tuberculosis -- Treatment of t...
    File Type:
    Filetype[PDF - 1.20 MB]
  3. Pneumococcal vaccination for cochlear implant candidates and recipients : updated recommendations of the Advisory Committee on Immunization Practices.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.. Centers for Disease Control and Prevention (U.S.).
    Published:
    August 8, 2003
    Source:
    MMWR. Morbidity and mortality weekly report. 2003; 52(31):739-40.
    Description:
    In October 2002, CDC recommended that all persons with cochlear implants receive age-appropriate pneumococcal vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) (Prevnar), 23-valent pneumococcal polysaccharide vaccine (PPV23) (Pneumovax)...
    Status:
    superseded
    File Type:
    Filetype[PDF - 587.17 KB]
  4. Core curriculum on tuberculosis; what the clinician should know
    Corporate Author:
    National Center for HIV, STD, and TB Prevention (U.S.), Division of Tuberculosis Elimination.
    Published:
    Fourth Edition, 2000, updated August 2003
    Description:
    This curriculum was designed to present basic information about TB for health care professionals. It is intended for use as a reference manual for clinicians caring for persons with or at high risk for TB disease or infection. In addition, it was des...
    File Type:
    Filetype[PDF - 1.07 MB]
  5. Treatment of tuberculosis
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.). American Thoracic Society.. Infectious Diseases Society of America..
    Published:
    June 20, 2003
    Source:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2003; 52(RR-11):1-77.
    Series:
    Morbidity and mortality weekly report. Recommendations and reports ; v. 52, no. RR-11
    American journal of respiratory and critical care medicine ; v. 167, p. 603-662
    Description:
    "The recommendations in this document are intended to guide the treatment of tuberculosis in settings where mycobacterial cultures, drug susceptibility testing, radiographic facilities, and second-line drugs are routinely available. In areas where th...
    Status:
    current
    File Type:
    Filetype[PDF - 1.46 MB]